The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate

Angiogenesis

Volumn 15, Issue 1, 2012, Pages 165-169

  Pasche, Nadine ^a   Frey, Katharina ^a   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

EDA domain of fibronectin; IL17; Immunocytokines; Vascular tumor targeting

Indexed keywords

ANTIBODY; FIBRONECTIN; INTERLEUKIN 17F; INTERLEUKIN 17F F8 ANTIBODY; UNCLASSIFIED DRUG; HYBRID PROTEIN; INTERLEUKIN 17;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IMMUNOPATHOGENESIS; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; CELL LINE; CELL PROLIFERATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; IMMUNOLOGY; METHODOLOGY; MOLECULAR CLONING; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SUBCUTANEOUS TISSUE; VASCULARIZATION;

MURINAE; MUS;

ANIMALS; ANTIBODIES; CELL LINE; CELL PROLIFERATION; CLONING, MOLECULAR; DRUG DELIVERY SYSTEMS; INTERLEUKIN-17; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT FUSION PROTEINS; SUBCUTANEOUS TISSUE;

EID: 84861538603     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-011-9239-8     Document Type: Article

References (26)

1. Murugaiyan G, Saha B (2009) Protumor vs antitumor functions of IL-17. J Immunol 183(7):4169-4175
2. Gaffen SL (2004) Biology of recently discovered cytokines: interleukin-17-a unique inflammatory cytokine with roles in bone biology and arthritis. Arthritis Res Ther 6(6):240-247
3. Onishi RM, Gaffen SL (2010) Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 129 (3):311-321
4. Yu JJ, Gaffen SL (2008) Interleukin-17: a novel inflammatory cytokine that bridges innate and adaptive immunity. Front Biosci 13:170-177
5. Gaffen SL (2008) An overview of IL-17 function and signaling. Cytokine 43(3):402-407
6. Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK, Sasaki H (2005) IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 175(9):6177-6189
7. Tartour E, Fossiez F, Joyeux I, Galinha A, Gey A, Claret E, Sastre-Garau X, Couturier J, Mosseri V, Vives V, Banchereau J, Fridman WH, Wijdenes J, Lebecque S, Sautes-Fridman C (1999) Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 59(15):3698-3704
8. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautes- Fridman C, Fossiez F, Haicheur N, Fridman WH, Tartour E (2002) Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 99(6):2114-2121
9. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT (2003) Interleukin-17 promotes angiogenesis and tumor growth. Blood 101(7):2620-2627
10. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W (2009) Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114(2):357-359
11. Ngiow SF, Smyth MJ, Teng MW (2010) Does IL-17 suppress tumor growth? Blood 115 (12):2554-2555; author reply 2556-2557
12. Kaspar M, Trachsel E, Neri D (2007) The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res 67(10):4940-4948
13. Schliemann C, Palumbo A, Zuberbuhler K, Villa A, Kaspar M, Trachsel E, Klapper W, Menssen HD, Neri D (2009) Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood 113(10):2275-2283
14. Ebbinghaus C, Ronca R, Kaspar M, Grabulovski D, Berndt A, Kosmehl H, Zardi L, Neri D (2005) Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer 116(2):304-313
15. Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L, Neri D (2002) Enhancement of the antitumor activity of interleukin- 12 by targeted delivery to neovasculature. Nat Biotechnol 20(3):264-269
16. Carnemolla B, Borsi L, Balza E, Castellani P, Meazza R, Berndt A, Ferrini S, Kosmehl H, Neri D, Zardi L (2002) Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 99(5):1659-1665
17. Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, Kosmehl H, Biro A, Siri A, Orecchia P, Grassi J, Neri D, Zardi L (2003) Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 102(13):4384-4392
18. Halin C, Gafner V, Villani ME, Borsi L, Berndt A, Kosmehl H, Zardi L, Neri D (2003) Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res 63(12):3202-3210
19. Marlind J, Kaspar M, Trachsel E, Sommavilla R, Hindle S, Bacci C, Giovannoni L, Neri D (2008) Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin Cancer Res 14(20):6515-6524
20. Pedretti M, Verpelli C, Marlind J, Bertani G, Sala C, Neri D, Bello L (2010) Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma. Br J Cancer 103(6):827-836
21. Rybak JN, Roesli C, Kaspar M, Villa A, Neri D (2007) The extradomain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res 67(22):10948-10957
22. Frey K, Zivanovic A, Schwager K, Neri D (2011) Antibodybased targeting of interferon-alpha to the tumor neovasculature: a critical evaluation. Integr Biol (Camb) 3(4):468-478
23. Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak JN, Rosli C, Borsi L, Neri D (2008) A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 122(11):2405-2413
24. Pasche N, Woytschak J, Wulhfard S, Villa A, Frey K, Neri D (2011) Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7. J Biotechnol 154(1): 84-92
25. Sommavilla R, Pasche N, Trachsel E, Giovannoni L, Roesli C, Villa A, Neri D, Kaspar M (2010) Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12. Protein Eng Des Sel 23(8):653-661
26. Dor Y, Djonov V, Keshet E (2003) Induction of vascular networks in adult organs: implications to proangiogenic therapy. Ann N Y Acad Sci 995:208-216